PF-07799933

DRUG2 trials

Sponsors

Pfizer

Conditions

Advanced Colorectal Cancer (Part 1)Advanced or Metastatic Solid TumorsBrain NeoplasmsDifferentiated Thyroid CancerGliomaHGGHigh Grade GliomaLGG

Phase 1

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Active, not recruitingNCT05355701

PfizerAdvanced Colorectal Cancer (Part 1), Glioma, Melanoma +2

Start: 2022-07-05End: 2027-08-31Updated: 2026-09-01

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

Active, not recruitingNCT05538130

PfizerAdvanced or Metastatic Solid Tumors, Brain Neoplasms, Differentiated Thyroid Cancer +10

Start: 2022-11-30End: 2027-08-31Updated: 2026-09-01

Related Papers

Phase 1b study of a brain-penetrant MEK inhibitor, PF-07799544, plus next-generation BRAF dimer inhibitor, PF-07799933, in advanced <i>BRAF</i> -mutant melanoma.

Journal of Clinical Oncology2026-05-28

A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799544 (ARRY-134) as a single agent and in combination with PF-07799933 BRAF dimer inhibitor, in participants 16 years and older with advanced solid tumors.

Journal of Clinical Oncology2024-06-012 citations

A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with <i>BRAF</i> -Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation

Cancer Discovery2024-05-0115 citations

Abstract CT178: Phase 1 trial of PF-07799933 (ARRY-440), a next-generation BRAF inhibitor, for BRAF-mutant cancers

Cancer Research2024-04-05

A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799933 (ARRY-440) as a single agent and in combination therapy in participants 16 years and older with advanced solid tumors with BRAF alterations.

Journal of Clinical Oncology2023-06-016 citations